# Spectrum Pharmaceuticals

Source: https://onco.cc/companies/spectrum-pharmaceuticals/  
OnCo record `spectrum-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023.

## Summary

Spectrum Pharmaceuticals, latterly based in Boston after years in Henderson, Nevada, marketed a haematology portfolio (Zevalin, Folotyn, Beleodaq, Marqibo and Evomela) that it sold to Acrotech Biopharma in 2019 to concentrate on two development programmes: poziotinib, an EGFR and HER2 exon 20 inhibitor that received a complete response letter in 2022, and eflapegrastim (Rolvedon), a long-acting G-CSF for chemotherapy-induced neutropenia approved by the FDA in September 2022. Assertio Holdings acquired the company in 2023. It appears on OnCo as one of the most frequent industry sponsors of phase 3 cancer trials on the registry.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc.
- Tags: ctgov-sponsor
- HQ: Boston, MA
- Type: biotech

## Sources

- ClinicalTrials.gov: trials led by Spectrum Pharmaceuticals: https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals
- Wikipedia: https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- companies: [Acrotech Biopharma](https://onco.cc/companies/acrotech-biopharma/)
- terms: [Neutropenia](https://onco.cc/terms/neutropenia/)

---
JSON: https://onco.cc/api/v1/entities/spectrum-pharmaceuticals.json